Article Text

Download PDFPDF
New hope for functional dyspepsia?
  1. Peter Bytzer
  1. Correspondence to Professor Peter Bytzer, Department of Medicine, Køge University Hospital, DK-4600 Køge, Denmark; peter.bytzer{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

“Hope is a good breakfast but a bad supper”

Francis Bacon (1561–1626)

Functional dyspepsia (FD) has been defined as persistent or recurrent symptoms of unknown cause thought to originate in the proximal gastrointestinal tract. Symptom patterns may vary but usually include epigastric pain or burning. Non-painful dyspeptic symptoms such as early satiation, nausea, postprandial fullness and vomiting suggest an underlying abnormality in gastroduodenal motility. The Rome III consensus committee suggests that FD is subdivided into an epigastric pain syndrome and a postprandial distress syndrome based on symptom patterns.1 These terms have replaced the previous categories of ‘ulcer-like’ and ‘dysmotility-like’ dyspepsia. Dyspeptic symptoms are very common in the general population with prevalence rates of 20–40%, and although FD is not associated with increased mortality or morbidity the symptoms have a major impact on health-related quality of life, utilisation of healthcare resources and work productivity.2

FD is probably a multifactorial disorder. Acid, Helicobacter pylori infection, visceral hypersensitivity, disturbances in gastric motility or accommodation and various psychosocial factors have all been implicated. Empiric antisecretory therapy, H pylori eradication or prokinetics remain the mainstay of treatment for FD, even though meta-analyses have shown limited or no symptomatic effects,3 4 and to date, …

View Full Text


  • Linked article 301454.

  • Competing interests PB has received unrestricted research grants from or has served on advisory boards for manufacturers of drugs, that may be used for functional dyspepsia (AstraZeneca, Eisai, Novartis Healthcare, Reckitt Benckiser).

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles